Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells

Experimental Hematology

Volumn 34, Issue 7, 2006, Pages 860-869

  Bund, Dagmar ^a   Mayr, Christine ^a,b   Kofler, David M ^a,b,c   Hallek, Michael ^a,b,c   Wendtner, Clemens Martin ^a,b,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD 229 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; HLA A2 ANTIGEN; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DIMERIZATION; ENZYME LINKED IMMUNOSPOT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

ANTIGENS, CD; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; LEUKEMIA, B-CELL, CHRONIC;

EID: 33745183799     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.04.010     Document Type: Article

References (39)

1. Rosenberg S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18 (1997) 175-182
2. Vonderheide R.H., Hahn W.C., Schultze J.L., and Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10 6 (1999) 673-679
3. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 411 (2001) 380-384
4. Van den Eynde B.J., and van der Bruggen P. T-cell-defined tumor antigens. Curr Opin Immunol 9 (1997) 684-693
5. + autologous T lymphocytes. Blood 105 (2005) 1566-1573
6. Krackhardt A.M., Witzens M., Harig S., et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 100 (2002) 2123-2131
7. Chrusciel J., Blonski J., Szymczyk P., Robak T., and Kilianska Z.M. A novel B-CLL-specific nuclear protein (p44/46). Leuk Res 23 9 (1999) 833-841
8. Van P., van der Bruggen P., Coulie P.G., et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145 (1995) 229-250
9. Hansen M.M. Chronic lymphocytic leukaemia: clinical studies based on 189 cases followed for a long time. Scand J Haematol 18 (1973) 286
10. de la Fuente M.A., Tovar V., Villamor N., et al. Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly9. Blood 97 (2001) 3513-3520
11. Williams A.F., and Barclay A.N. The immunoglobulin superfamily-domains for cell surface recognition. Ann Rev Immunol 88 (1998) 381-405
12. Sandrin M.S., GumLey T.P., Henning M.M., et al. Isolation and characterization of cDNA clones for mouse Ly9. J Immunol 149 (1992) 1636-1641
13. Davis S.J., and van der Merwe P.A. The structure and ligand interactions of CD2: implications for T-cell function. Immunol Today 617 (1996) 177-187
14. Tovar V., de la Fuente M.A., Pizcueta P., Bosch J., and Engel P. Gene structure of the mouse leukocyte cell surface molecule Ly9. Immunogenetics 51 (2000) 788-793
15. Romero X., Benitez D., March S., Vilella R., Miralpeix M., and Engel P. Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). Tissue Antigens 64 (2004) 132-144
16. Weiss A., and Littman D.R. Signal transduction by lymphocyte antigen receptors. Cell 76 (1994) 263-274
17. Tangye S.G., Phillips J.H., and Lanier L.L. The CD2-subset of the Ig superfamily of cell surface molecules: receptor-ligand pairs expressed by NK cells and other immune cells. Semin Immunol 12 (2000) 149-157
18. Ledbetter J.A., Golding J.W., Tsu T.T., and Herzenberg L.A. A new mouse lymphoid alloantigen (Lgp100) recognized by a monoclonal rat antibody. Immunogenetics 8 (1979) 347-360
19. Sandrin M.S., Henning M.M., Lo M.F., Baker E., Sutherland G.R., and McKenzie I.F. Isolation and characterization of cDNA clones for Humly9: the human homologue of mouse Ly9. Immunogenetics 43 (1996) 13-19
20. Songyang Z., Shoelson S.E., McGlade J., et al. Specific motifs recognized by SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, Syk, and Vav. Mol Cell Biol 14 (1994) 2777-2785
21. Cheson B., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
22. Rammensee H.G., Friede, and Stevanovic S. MHC ligands and peptide motifs: 1st listing. Immunogenetics 41 (1995) 178-228
23. Van der Bruggen P., Bastin J., Gajewski T., et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24 (1994) 3038-3043
24. Hirohashi Y., Torigoe T., Maeda A., et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 8 (2002) 1731-1739
25. Sato T., Sato N., Takahashi S., Koshiba H., and Kikuchi K. Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells. Cancer Res 46 (1986) 4384-4389
26. Garrone P., Neidhardt E.M., Garcia E., Galibert L., von Kooten C., and Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 182 (1995) 1265-1273
27. + T cells specific for EBV in healthy virus carriers. J Immunol 162 (1999) 1827-1835
28. Angelopoulou M.K., Kontopidou F.N., and Pangalis G.A. Adhesion molecules in B-chronic lymphoproliferative disorders. Semin Hematol 36 (1999) 178-197
29. Clay T.M., Hobeika A.C., Mosca P.J., Lyerly H.K., and Morse M.A. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 7 (2001) 1127-1135
30. Mayr C., Speicher M.R., Kofler D.M., et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 107 (2006) 742-751
31. Granziero L., Ghia P., Circosta P., et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97 (2001) 2777-2783
32. Kappler J.W., Roehm N., and Marrack P. T-cell tolerance by clonal elimination in the thymus. Cell 49 (1987) 273-280
33. Stockinger B. T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv Immunol 71 (1999) 229-265
34. Fraser C.C., Howie D., Morra M., et al. Identification and characterization of SF2000 and SF2001, two new members of the immune receptor SLAM/CD2 family. Immunogenetics 53 (2002) 843-850
35. Rudd P.M., Wormald M.R., Stanfield R.L., et al. Roles for glycosylation of cell surface receptors involved in cellular immune recognition. J Mol Biol 293 (1999) 351-366
36. Wang N., Morra M., Wu C., et al. CD150 is a member of a family of genes that encode glycoproteins on the surface of hematopoietic cells. Immunogenetics 53 (2001) 382-394
37. Schultze J.L., Michalak S., Seamon M.J., et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100 (1997) 2757-2765
38. Kato K., Cantwell M.J., Sharma S., and Kipps T.J. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 101 (1998) 1133-1141
39. Jewell A.P., and Yong K.L. Regulation and function of adhesion molecules in B-cell chronic lymphocytic leukaemia. Acta Haematol 97 (1997) 67-72